​

Apogee Therapeutics (APGE) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

APGE Stock Forecast

Apogee Therapeutics (APGE) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $122.75, with a high of $140.00 and a low of $81.00. This represents a -8.60% decline from the last price of $134.30.

- $30 $60 $90 $120 $150 High: $140 Avg: $122.75 Low: $81 Last Closed Price: $134.3

APGE Stock Rating

Apogee Therapeutics stock's rating consensus is Hold, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (21.43%), 11 Hold (78.57%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 14 0 11 3 Strong Sell Sell Hold Buy Strong Buy

APGE Price Target Upside V Benchmarks

TypeNameUpside
StockApogee Therapeutics-8.60%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-1121
Avg Price Target-$122.93$112.68
Last Closing Price$134.30$134.30$134.30
Upside/Downside--8.47%-16.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26-312--15
Jun, 26-154--19
May, 26-153--18
Apr, 26-143--17
Mar, 26-142--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 24, 2026Stifel Nicolaus$135.00$132.971.53%0.52%
Jun 24, 2026Joseph CatanzaroMizuho Securities$135.00$132.881.60%0.52%
Jun 23, 2026RBC Capital$135.00$132.551.85%0.52%
Jun 23, 2026UBS$135.11$132.551.93%0.60%
Jun 22, 2026David HoangDeutsche Bank$135.00$132.551.85%0.52%
Jun 22, 2026Craig-Hallum$135.11$132.651.85%0.60%
Jun 08, 2026Brian AbrahamsRBC Capital$97.00$86.9211.60%-27.77%
May 28, 2026Goldman Sachs$89.00$77.5014.84%-33.73%
May 27, 2026Danielle BrillTruist Financial$81.00$78.073.75%-39.69%
May 27, 2026Wedbush$135.00$81.7365.18%0.52%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 23, 2026Cowen & Co.Holddowngrade
Jun 23, 2026GuggenheimBuyNeutraldowngrade
Jun 23, 2026RBC CapitalSector PerformSector Performdowngrade
Jun 23, 2026CitigroupBuyNeutraldowngrade
Jun 23, 2026UBSBuyNeutraldowngrade
Jun 22, 2026Deutsche BankBuyHolddowngrade
Jun 22, 2026Craig-HallumBuyHolddowngrade
Jun 22, 2026WedbushOutperformNeutraldowngrade
Jun 08, 2026RBC CapitalSector PerformSector Performhold
May 27, 2026WedbushOutperformOutperformhold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.66$-3.30$-4.22---
Avg Forecast$-3.26$-3.10$-4.32$-5.36$-6.49$-7.03
High Forecast$-1.93$-2.90$-3.38$-3.52$-4.30$-7.03
Low Forecast$-3.85$-3.32$-4.77$-10.81$-12.46$-7.03
Surprise %-49.08%6.45%-2.31%---

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast------
High Forecast------
Low Forecast------
Surprise %------

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-83.98M$-182.15M----
Avg Forecast$-83.98M$-77.65M$-101.84M$-179.14M$-209.56M$-175.70M
High Forecast$-48.25M$-72.39M$-84.47M$-87.90M$-107.52M$-175.70M
Low Forecast$-96.19M$-82.91M$-119.20M$-270.39M$-311.60M$-175.70M
Surprise %-134.57%----

APGE Forecast FAQ

Is Apogee Therapeutics stock a buy?

Apogee Therapeutics stock has a consensus rating of Hold, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Apogee Therapeutics is a neutral investment for most analysts.

What is Apogee Therapeutics's price target?

Apogee Therapeutics's price target, set by 14 Wall Street analysts, averages $122.75 over the next 12 months. The price target range spans from $81 at the low end to $140 at the high end, suggesting a potential -8.60% change from the previous closing price of $134.3.

How does Apogee Therapeutics stock forecast compare to its benchmarks?

Apogee Therapeutics's stock forecast shows a -8.60% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Apogee Therapeutics over the past three months?

  • July 2026: 0% Strong Buy, 20.00% Buy, 80.00% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 0% Strong Buy, 78.95% Buy, 21.05% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 0% Strong Buy, 83.33% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Apogee Therapeutics’s EPS forecast?

Apogee Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.36, marking a 27.01% increase from the reported $-4.22 in 2025. Estimates for the following years are $-6.49 in 2027, and $-7.03 in 2028.

What is Apogee Therapeutics’s revenue forecast?

Apogee Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, and $0 for 2028.

What is Apogee Therapeutics’s net income forecast?

Apogee Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-179M, representing a 0% decrease from the reported $0 in 2025. Projections indicate $-210M in 2027, and $-176M in 2028.